



New Zealand standardised oral formulation batch sheet

Flecainide suspension 20 mg/mL (20 mL)

Patient's name		Storage condition	In a refrigerator	At room temperature
NHI		Temperature	2-8°C	≤ 25°C
Date compounded		Shelf life	Precipitates	30 days
Batch number		Recommended storage	There is a risk of precipitation if the solution is stored in a refrigerator	<input checked="" type="checkbox"/>

Ingredients required and formula:

Ingredient	Supplier	Batch number	Expiry date	Standard formula	Quantity dispensed	Dispensed by	Checked by
Flecainide acetate 50 mg tablets				8 tablets			
Ora-Blend®	Perrigo			to 20 mL			
OR							
Ora-Plus®	Perrigo			10 mL			
Ora-Sweet®	Perrigo			10 mL			

Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted? Yes

Calculations performed by

Calculations checked by (pharmacist)

Area cleared for processing by

Instructions to compound suspension:

Note: stability of this formula has been established for Tambocor and Flecainide BNM brands of flecainide acetate

1. **If Ora-Blend® unavailable:** Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.
2. Crush tablets in mortar to a fine powder.
3. Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.
4. Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.
5. Make up to the final volume and mix well.
6. Label and package product appropriately.

Labels

Attach product label and auxiliary labels:

Label checked by



New Zealand standardised oral formulation batch sheet

Flecainide suspension 20 mg/mL (20 mL)

Final yield	_____ mL	Checked by	
Final appearance of product	White to pale pink.		
Container	Amber plastic mission bottle.		
Compounded by	Name:	Signature:	Date:
Final check and product release	Name:	Signature:	Date:
Special instructions/precautions			
<ol style="list-style-type: none">1. Shake well before use.2. Store at room temperature. Storage at room temperature is recommended as precipitation has been observed if stored in a refrigerator.3. Oral liquid can make the mouth numb so it is best taken 30 minutes before or 30 minutes after food.4. A 25 mg/5 mL oral liquid is available (Section 29). Ensure there is no potential for confusion with these different strengths particularly if patient has previously used the commercial product.			
References:			
<ol style="list-style-type: none">1. Allen LV, Jr., Erickson MA, 3rd. <i>Am J Health Syst Pharm</i>, 1996; 53(18): 2179-2184.2. Medicines for Children. 2012 [accessed 02/08/2018]; Available from: https://www.medicinesforchildren.org.uk/flecainide-arrhythmias.3. New Zealand Formulary for Children (NZFC). 2018 [accessed 01/08/2018]; Available from: https://www.nzfchildren.org.nz.4. Muta T, Bergamin A, Garg S. Stability testing of flecainide acetate suspension - Final Report. December 2019. University of South Australia. Unpublished; data on file Compounding working group.			
Prepared by	New Zealand Compounding Working Group		
Approved by	National Medication Safety Advisory Group of the Health Quality & Safety Commission New Zealand		
Hosted by	Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website		
Version number	4.0	Version approval date	21/01/20
Document review due	01/02/22		

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.